Edition:
United States

Morphosys AG (MORG.DE)

MORG.DE on Xetra

41.51EUR
1 Dec 2016
Change (% chg)

€-0.50 (-1.18%)
Prev Close
€42.00
Open
€41.99
Day's High
€42.38
Day's Low
€40.80
Volume
104,667
Avg. Vol
126,276
52-wk High
€62.30
52-wk Low
€32.90

MORG.DE

Chart for MORG.DE

About

MorphoSys AG (MorphoSys) develops and commercializes antibodies for therapeutic applications. The Company's operating segments include Proprietary Development and Partnered Discovery. The Company develops new treatments for patients suffering from serious diseases. The Company has a total of approximately 100 individual... (more)

Overall

Beta: 0.70
Market Cap(Mil.): €1,247.27
Shares Outstanding(Mil.): 26.54
Dividend: --
Yield (%): --

Financials

  MORG.DE Industry Sector
P/E (TTM): -- 42.21 29.87
EPS (TTM): -1.73 -- --
ROI: -12.39 -1.09 14.95
ROE: -12.76 -2.39 16.29

CORRECTED-BRIEF-Morphosys reports 32.3 mln eur EBIT loss in first 9 months of 2016

* Says for first nine months of 2016, group revenues totaled eur 36.7 million euros ($40.63 million) and EBIT amounted to eur -32.3 million

Nov 07 2016

BRIEF-Morphosys receives milestone for start of Phase 1 trial

* Says receives clinical milestone for start of Phase 1 trial with novel cancer antibody Source text for Eikon: Further company coverage:

Oct 20 2016

BRIEF-Morphosys ag in ongoing phase 1/2a study, anti-cd38 antibody continues to show encouraging clinical response rates in heavily pre-treated multiple myeloma patients

* In ongoing phase 1/2a study, anti-cd38 antibody continues to show encouraging clinical response rates in heavily pre-treated multiple myeloma patients Source text for Eikon: Further company coverage:

Oct 17 2016

Morphosys moves closer to getting first antibody drug on market

FRANKFURT German biotech Morphosys moved a step closer to getting its first antibody drug onto the market as its licensee, Johnson & Johnson unit Jenssen, reported positive results from a phase 3 study of psoriasis drug guselkumab.

Oct 01 2016

Morphosys moves closer to getting first antibody drug on market

FRANKFURT, Oct 1 German biotech Morphosys moved a step closer to getting its first antibody drug onto the market as its licensee, Johnson & Johnson unit Jenssen, reported positive results from a phase 3 study of psoriasis drug guselkumab.

Oct 01 2016

BRIEF-Morphosys, Galapagos start first-in-patient dosing of il-17c antibody MOR106

* Morphosys and Galapagos start first-in-patient dosing of il-17c antibody MOR106 in atopic dermatitis

Sep 29 2016

BRIEF-Morphosys, Galapagos start first-in-patient dosing of IL-17C antibody MOR106 in atopic dermatitis

* Says Morphosys and Galapagos start first-in-patient dosing of IL-17C antibody MOR106 in atopic dermatitis

Sep 29 2016

BRIEF-Morphosys H1 EBIT at -19.2 mln eur

* Says group revenue in first half of 2016 totaled eur 24.3 million and EBIT amounted to eur -19.2 million

Aug 01 2016

BRIEF-Morphosys sees FY 2016 revenue eur 47-52 million

* Sees fy 2016 revenue eur 47 million to eur 52 million Source text for Eikon: Further company coverage:

Aug 01 2016

BRIEF-Morphosys shares up 4.4 pct after Novartis milestone payment

* Shares rise 4.4 percent at open following Novartis milestone payment for clinical trial Source text for Eikon: Further company coverage:

Jul 04 2016

Earnings vs. Estimates